Teaming up to tackle cardiorenal risk in diabetes - Role of SGLT2i: How to overcome clinical inertia

1-4 of 4

• 

  RestartResume

  Introduction on tackling cardiorenal risk in diabetes

  RestartResume

  Introduction on tackling cardiorenal risk in diabetes

  Teaming up to tackle cardiorenal risk in diabetes - Role of SGLT2i: How to overcome clinical inertia

  Introduction on tackling cardiorenal risk in diabetes

  Prof. Melanie Davies, MD

  • 

    

    Prof. Melanie Davies, MD

• 

  RestartResume

  Dialogue on how to overcome clinical inertia with regard to SGLT2i

  RestartResume

  Dialogue on how to overcome clinical inertia with regard to SGLT2i

  Teaming up to tackle cardiorenal risk in diabetes - Role of SGLT2i: How to overcome clinical inertia

  Dialogue on how to overcome clinical inertia with regard to SGLT2i

  Prof. Melanie Davies, MD; Prof. Nikolaus Marx, MD

  • 

    

    Prof. Melanie Davies, MD

  • 

    

    Prof. Nikolaus Marx, MD

• 

  RestartResume

  SGLT2i: Overview of recent trials and guideline recommendations

  RestartResume

  SGLT2i: Overview of recent trials and guideline recommendations

  Teaming up to tackle cardiorenal risk in diabetes - Role of SGLT2i: How to overcome clinical inertia

  SGLT2i: Overview of recent trials and guideline recommendations

  Prof. Nikolaus Marx, MD

  • 

    

    Prof. Nikolaus Marx, MD

• 

  RestartResume

  Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

  RestartResume

  Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

  Teaming up to tackle cardiorenal risk in diabetes - Role of SGLT2i: How to overcome clinical inertia

  Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

  Prof. Melanie Davies, MD; Prof. Nikolaus Marx, MD

  • 

    

    Prof. Melanie Davies, MD

  • 

    

    Prof. Nikolaus Marx, MD